Invus

Portfolio Co Investors 2026 for Invus: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Invus accounts for 49 tracked companies with verified cap-table data, 49 of which disclose round sizes totalling $14B. The median disclosed raise is $194M, and the largest is Morphic Therapeutic at $3.2B, ahead of Moderna Therapeutics ($650M) and Mirador Therapeutics ($650M).

The names that recur most often on these co-invested cap tables are Invus (49 companies), RA Capital Management (9 companies), Janus Henderson Investors (9 companies), Redmile Group (7 companies), Alexandria Venture Investments (7 companies), Polaris Partners (6 companies). By latest disclosed round, the market skews Series B (17), Series C (11), Series A (10), Series D (3).

Best funded Invus companies

  1. Morphic Therapeutic — $3.2B (latest: Series B)
  2. Moderna Therapeutics — $650M (latest: Series G)
  3. Mirador Therapeutics — $650M (latest: Series B)
  4. BioNTech — $595M (latest: Series B)
  5. BioNTech.de — $595M (latest: Series B)
  6. Zero Motorcycles — $584M (latest: Series G)
  7. Neumora Therapeutics — $500M (latest: Series A)
  8. Talaris Therapeutics — $365M (latest: Other Equity)
  9. Sironax — $301M (latest: Series B)
  10. LifeMine Therapeutics — $300M (latest: Series C)
  11. Endeavor BioMedicines — $292M (latest: Series A)
  12. Flare Therapeutics — $287M (latest: Series C)
  13. Triveni Bio — $277M (latest: Series C)
  14. Cava Group — $265M (latest: Series F)
  15. NiKang Therapeutics — $260M (latest: Series C)

Invus — related firms and companies (51)

Invus profile · All research reports